Individualized Therapy Key to Standards of Care for Obesity Drugs

As obesity medications become a routine component of clinical practice, individualized therapy has emerged as the central guiding principle in newly established standards of care. These medications are now recognized as essential tools within a comprehensive care plan, offering benefits that significantly exceed what can be achieved through lifestyle interventions alone for many individuals. Clinicians are urged to move away from one-size-fits-all models, instead utilizing a person-centered, shared decision-making approach to select medications that align with a patient’s specific medical profile, health goals, and life circumstances.

A New Standard of Individualized Care

The Obesity Association, a subsidiary of the American Diabetes Association (ADA), has established thorough, evidence-based standards for the use of obesity pharmacotherapy in adult patients. Research indicates that when medical treatments are paired with lifestyle changes, they are effective at both achieving and maintaining weight loss while simultaneously improving various obesity-related comorbidities. To maximize these clinical benefits, providers are encouraged to use a person-centered, shared decision-making model that prioritizes the unique medical needs and personal preferences of each individual.

Why It Matters

Obesity is a complex, chronic, and relapsing disease that impacts multiple organ systems. Obesity increases the risk of hypertension, type 2 diabetes, coronary heart disease, stroke, and certain cancers. In the United States, nearly 1 in 3 adults (30.7%) are overweight, while more than 2 in 5 adults (42.4%) have obesity.

Multiple Factors

Excessive weight gain in both adults and youth is driven by a complex interplay of factors, including genetic predispositions and nutritional choices regarding the types and quantities of food and drink consumed. Beyond diet, weight is influenced by physical activity levels and the prevalence of sedentary habits, such as screen time or mobile device usage. Additionally, weight trajectories are shaped by sleep hygiene, underlying medical conditions, and the use of weight-promoting medications. These individual factors are further complicated by social determinants of health, such as an individual’s environment and their ability to access or afford nutritious foods and safe spaces for exercise.

The necessity for pharmacotherapy is rooted in human physiology. When individuals lose weight, multiple weight-regulating hormones change in a way that creates a physiologic environment urging the body to return to its previous higher weight. Furthermore, weight reduction can negatively affect basal metabolic rate and energy expenditure, making long-term maintenance exceptionally difficult without medical assistance.

Biology and Long-Term Success

The recent expansion of FDA-approved medications, particularly those targeting neurohormonal systems like Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) pathways, has fundamentally changed the therapeutic landscape. These agents do not merely suppress appetite; they target the dysregulated systems that cause weight gain and prevent sustained reduction.

Individualized therapy matters because it addresses specific obesity-related diseases and complications, rather than focusing solely on a number on a scale. For example, the amount of weight reduction needed varies by condition:

• ≥ 5 % reduction: Can achieve clinically meaningful health benefits and improve cardiometabolic risk factors.
• ≥ 10 % reduction: Often required to manage more intensive complications like metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, heart failure with preserved ejection fraction (HFpEF), and knee osteoarthritis.
• ≥ 15 % reduction: May be indicated for greater therapeutic benefit in moderate-to-severe conditions, such as obstructive sleep apnea (OSA).

Who It Affects

A Multidisciplinary Ecosystem

The primary group affected is the millions of adults living with obesity or overweight with comorbidities. However, the 2026 standards emphasize that effective treatment requires an interprofessional team.

For Clinicians and Specialists

Health care professionals must now be knowledgeable in a wide array of pharmacological profiles, including mechanisms of action, contraindications, and dosing schedules. For instance, a provider must know that phentermine and naltrexone-bupropion are contraindicated in patients with uncontrolled hypertension, while liraglutide, semaglutide, and tirzepatide require careful monitoring for gastrointestinal (GI) disease and a history of medullary thyroid carcinoma.

For Payers and Employers

Stakeholders who determine insurance coverage are key players. Research indicates that the high out-of-pocket costs and lack of insurance coverage are primary drivers of medication discontinuation. The ADA standards explicitly state that because obesity is a chronic disease, medication should be continued long-term to maintain health benefits; stopping medication typically results in weight recurrence and the worsening of cardiometabolic risk factors.

For Special Populations

Specific care is required for individuals of childbearing potential. Obesity medications are contraindicated during pregnancy and lactation. Some agents, such as topiramate, are linked to fetal harm, and others, like tirzepatide, can significantly interact with and reduce the efficacy of oral contraceptives.

What Changes

Based on the comprehensive 2026 standards, below is a summary of FDA-approved obesity medications and their demonstrated or potential benefits across various comorbidities.

Key Clinical Considerations for Selection

• Heart Rate and Blood Pressure: Tirzepatide, semaglutide, liraglutide, and phentermine-topiramate can cause small increases in resting heart rate (~2–4 bpm). However, tirzepatide, semaglutide, and orlistat have demonstrated benefits for lowering blood pressure.
• Weight-Promoting Medication Review: Before prescribing, clinicians should evaluate current medications. For example, switching from weight-promoting beta-blockers (like metoprolol) to weight-neutral ACE inhibitors or ARBs is recommended for patients with hypertension.
• Monitoring and Escalation: Follow-up should occur at least monthly for the first three months to manage adverse effects and support medication-taking behavior. If weight loss is <5 % after 3–6 months, clinicians should consider treatment intensification or switching agents.
• Nutritional Support: Because high-potency medications (tirzepatide, semaglutide) can lead to significant lean body mass loss (25–30% of total weight loss), patients should aim for 1.2–1.6 g/kg of protein daily and engage in resistance training.

Implementation and Clinical Strategy

The new standards demand a shift in how clinical practices operate. Key changes include:

1. Comprehensive Medical Evaluation*

Before a single prescription is written, clinicians must perform a holistic assessment. This includes:

• Anthropometrics: Measuring height, weight, BMI, and waist circumference (to identify central adiposity).
• Laboratory Testing: Checking A1C, liver enzymes (ALT/AST), renal function (eGFR), and lipid panels.
• Medication Review: Identifying weight-promoting medications such as certain beta-blockers, insulin, or antipsychotics and switching to weight-neutral alternatives (like ACE inhibitors or SGLT2 inhibitors) when clinically appropriate.

2. Matching Medication to Comorbidities*

Prescribing is now driven by the patient’s specific comorbidity profile:

• Diabetes/Prediabetes: Prioritize GLP-1 receptor agonists (GLP-1RAs) or dual GIP/GLP-1RAs due to their superior glucose-lowering and weight-reduction efficacy.
• Atherosclerotic Cardiovascular Disease (ASCVD): Use agents like semaglutide, which has demonstrated a 20% reduction in major adverse cardiovascular events (MACE).
• Heart Failure (HFpEF): GLP-1RAs or dual GIP/GLP-1RAs are recommended for their demonstrated ability to improve heart failure symptoms and reduce events.
• Obstructive Sleep Apnea: Tirzepatide is prioritized for its significant reduction in the apnea-hypopnea index (AHI).

3. Integrated Lifestyle and Nutritional Care*

Medications are not a standalone solution; they must be used in conjunction with lifestyle modifications. Adding medications to lifestyle interventions improves both initial weight reduction and long-term maintenance.

• Nutritional Support: Clinicians should consider referral to a Registered Dietitian Nutritionist (RDN). Because medications can cause significant appetite suppression, patients must be monitored to prevent protein insufficiency (aiming for 1.2–1.6 g/kg of protein daily) and micronutrient deficiencies.
• Physical Activity: To minimize the loss of lean body mass (which can account for 25%–30% of total weight loss), plans must include muscle-strengthening and resistance activities.

4. Structured Monitoring and Escalation*

The “prescribe and forget” model is replaced by a rigorous follow-up schedule:

• Phase 1 (Months 1–3): Monthly visits (in-person or via telehealth) to assess efficacy, manage side effects (such as nausea or constipation), and support medication-taking behavior.
• Phase 2 (Year 1): Follow-up at least every 3 months.
• Phase 3 (Long-term): Follow-up every 6 months.

If a patient has an inadequate response (typically defined as failing to reach a 5% weight loss within 3–6 months), clinicians should avoid treatment inertia. Strategies include intensifying to the maximum tolerated dose, switching to an alternative medication, or referring for metabolic-bariatric surgery.

The Path Forward: Equity and Transparency

Individualized care must also address sociocultural factors and personal motivation. Culturally tailored interventions that respect lived experiences are essential to prevent widening health disparities. For practices unable to provide this level of comprehensive infrastructure, the standards recommend referring patients to specialists with specific competency in obesity medicine.

Ultimately, these standards frame obesity management as a long-term journey. By using shared decision-making to align powerful new pharmacotherapies with individual patient needs, the medical community can move toward a future where treatment goals extend beyond weight reduction to include profound improvements in physical function, cardiovascular health, and overall well-being.

References

1. https://pubmed.ncbi.nlm.nih.gov/41529914/
2. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity
3. https://www.cdc.gov/nchs/products/databriefs/db508.htm